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T he androgen receptor (AR) belongs to a nuclear receptor superfamily and functions as a liganddependent transcription factor (1) (2) (3) (4) . The AR-regulated transcriptional program is associated with various diseases, especially prostate cancer (1, 2, 5, 6) . Suppression of AR is an effective therapy for AR-dependent prostate cancer. However, in most cases it relapses as castrationresistant prostate cancer (CRPC), acquiring resistance to hormone therapy. One of the leading causes of the pathogenesis of CRPC is enhanced AR signaling due to AR overexpression or production of AR variants (1) (2) (3) 5) . This indicates the importance of AR in CRPC development.
Therefore, many studies have investigated the global ARbinding sites (ARBSs) in prostate cancer cells by performing chromatin immunoprecipitation (ChIP) analysis coupled with a tiling array or with a next-generation sequencer (ChIP-seq) (5) (6) (7) (8) . Sequence analysis of AR-binding regions in the human genome have identified multiple transcription factor motifs, such as forkhead box protein A1 (FOXA1), GATA-binding protein 2 (GATA2), Runtrelated transcription factor 1 (RUNX1), Homeobox protein NKX3-1, and Octamer transcription factor 1 (OCT1) (8) (9) (10) . Global mapping of FOXA1-binding sites reveals overlaps with ARBSs, thus highlighting the roles of these collaborative factors in activating AR signaling (5, 10) .
OCT1 is a member of the POU-homeodomain family, regulating a wide variety of ubiquitously expressed genes and tissue-specific genes (11) . A previous ChIP analysis coupled with a tiling array study identified the ARBSs and revealed that OCT1 is a ligand-dependent ARinteracting partner (9) . OCT1 is recruited to represent AR-regulated promoters such as prostate-specific antigen or transmembrane protease, serine 2 (9) . Inhibition of OCT1 expression reduced AR recruitment to binding sites and diminished AR transcriptional activity (12) .
We previously analyzed the clinical significance of OCT1 in prostate cancer and found that OCT1 could be used as a biomarker for predicting poor survival postoperatively (13) . In addition, we showed that knockdown of OCT1 inhibited androgen-dependent LNCaP cell proliferation, suggesting that OCT1 plays an important role in androgen-dependent cell proliferation. Furthermore, we revealed that the enhancer of acyl-CoA synthetase long chain family member 3 (ACSL3) is cooperatively regulated by OCT1 and AR (12, 14) . Loss of ACSL3 retards prostate cancer tumor growth in vivo, suggesting that ACSL3 mediates OCT1/AR-dependent tumor growth. In these reports, AR-dependent prostate cancer cell lines, such as LNCaP and VCaP cells, were used mainly to investigate the OCT1 transcriptional program. Therefore, it is still unclear how OCT1 regulates target genes and programs in CRPC. Here, we investigated the global function of OCT1 in CRPC model 22Rv1 cells at the genome-wide level by combining ChIP-seq with expression analysis. We identified multiple OCT1 target genes that are induced by OCT1 and AR in CRPC cells. We also explored the mechanism of development of CRPC through OCT1 genomic function.
Materials and Methods

Cell culture, reagents, and antibodies
The prostate cancer cell lines LNCaP and 22Rv1 were obtained from American Type Culture Collection (Rockville, MD) and were maintained as mentioned in previous experimental studies (15, 16) . All cell lines were validated for identity by short tandem repeat analysis or routinely checked for Mycoplasma contamination. Charcoal-stripped fetal bovine serum was produced using dextran-coated charcoal, purchased from Sigma (St. Louis, MO). Nocodazole and DHT were purchased from Wako (Osaka, Japan 
ChIP assay
ChIP and quantitative PCR (qPCR) were performed as previously described (15) . The fold enrichment relative to input was measured by performing qPCR using KAPA SYBR Green PCR master mix (KAPA Biosciences, Hamburg, Germany) and the ABI StepOne System (Life Technologies, St. Louis, MO). The primer sequences for quantifying OCT1-binding regions by using qPCR were previously described (12) and are listed as follows:
ANLN promoter forward: 5 0 -GCAGGGGAGATGCTAA-TGAA-3 0 ANLN promoter reverse: 5 0 -TGCTCGGTACACTTGCATTG-3 0 ANLN intron forward: 5 0 -ACCTTCTGGCACACTTCCAC-3 0 ANLN intron reverse: 5 0 -ACCTACCCCATAACCGCTTC-3 0
ChIP-seq
We performed AR, OCT1, and antihistone acetylated H3 ChIP-seq in 22Rv1cells using an Illumina HiSeq 2500 system (San Diego, CA) as described in previous studies (24) (25) (26) . We performed AR and OCT1 ChIP-seq in LNCaP as mentioned in the previous study (12) . These sequence results are deposited in National Center for Biotechnology Information's Gene Expression Omnibus (GSE123565, GSE77771). All sequence libraries were made according to Illumina's instructions. Unfiltered single-end sequencing of 36 bp was conducted for all samples. The sequenced reads obtained were aligned to the human reference genome (hg19) using Bowtie. Signal scores of OCT1 bindings were calculated using model-based analysis of ChIP-seq (27) , and the threshold for the binding sites was set at P , 1.0E-5. An integrative genomic viewer was used for visualization as previously described (28) . Motif discovery (650 bp around peaks obtained by ChIP-seq) was conducted with the hypergeometric optimization of motif enrichment (HOMER) (29) . Heat signatures of ChIP-seq signaling were obtained for 5000 bp to the left and right of each peak center of the AR bindings using HOMER.
Microarray
For gene expression microarrays, the GeneChip Human Clariom S Array (Affymetrix, Santa Clara, CA) was used according to the manufacturer's protocol. Data analysis was performed using the Affymetrix Microarray Suite software. To compare arrays, normalization was performed on data from all the probe sets. The data were deposited in National Center for Biotechnology Information's Gene Expression Omnibus (GSE123517). Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID 6.7; http://david.ncifcrf.gov/).
Short interfering RNA
To silence OCT1 expression, three short interfering RNA (siRNA) oligonucleotides that recognize different sequences in OCT1 (siOCT1 #1: 5 0 -GUGAAGGCUAGGUGAGAA-3 0 ; siOCT1 #2: 5 0 -GUGCUAGAUAGGUUUAUAAGU-3 0 ; and siOCT1 #3: 5 0 -CUCGCUAUGGGGAAACUAUAU-3 0 ) and a negative control siRNA (i.e., siControl) were purchased from Sigma Genosys (Tokyo, Japan) as described in previous studies (12, 24, 25) . siANLN #1(s28982), siANLN #2(s28983), siAR #1(s1539), and siAR #2(s1538) were purchased from Thermo Fisher (St. Louis, MO). These siRNAs were transfected into cells using Lipofectamine RNAiMAX (Invitrogen, St. Louis, MO), per the manufacturer's protocol.
RNA extraction and quantitative RT-PCR
Total RNA extraction was performed using ISOGEN reagent (Nippon Gene, Tokyo, Japan) per the manufacturer's instructions. We synthesized first-strand cDNA by using Pri-meScript (Takara, Kyoto, Japan). To analyze the gene expression level, cDNA was subjected to quantitative RT-PCR (qRT-PCR) using Applied Biosystems StepOne (Life Technologies). qRT-PCR was performed as previously described (12, 15, 16) . Measured mRNA expression levels were normalized by glyceraldehyde 3-phosphate dehydrogenase (12) . The following PCR primer sequences were used for qRT-PCR:
Western blot analysis
Whole cell lysates were prepared using lysis buffer [50 mM Tris-HCl (pH, 8.0), 150 mM NaCl, 1% Triton X-100, 1.5 mM MgCl 2 , 10 mg/mL aprotinin, 10 mg/mL leupeptin, and 1 mM phenylmethylsulfonyl fluoride]. Protein concentration was determined by performing the BCA assay (Pierce, Grosse Pointe, MI). Obtained lysates were loaded on SDS-polyacrylamide gels, separated using electrophoresis, and subsequently electrotransferred onto Immobilon-P Membranes (Millipore). Membranes were incubated with the specific primary antibodies at 4°C overnight (anti-OCT1 1:500, anti-ANLN 1:300, anti-AR 1:1000) and then incubated with secondary antibodies. Antibodyantigen complexes were detected using Western Blotting Detection Reagents (Pierce).
Immunofluorescence
Cells cultured on 12-mm circular coverslips (Fisher Scientific) in 24-well plates were fixed with 4% paraformaldehyde for 10 minutes at room temperature. Cells were then permeabilized with 0.5% Triton X-100/PBS for 2 minutes. After washing cells with PBS, we blocked cells in 5% normal goat serum/PBS for 30 minutes. Cells were incubated with anti-ANLN antibody (1:100) in 5% normal goat serum/ PBS overnight at 4°C. Then cells were washed 3 times with PBS and incubated with anti-mouse IgG conjugated to Alexa Fluor 546 (Life Technologies) in goat serum/PBS for 1 hour. To stain actin with phalloidin (Cytoskeleton, Denver, CO), we treated cells with phalloidin (100 nM) for 30 minutes according to the manufacture's protocol. Nuclei were counterstained with 4 0 ,6diamidino-2-phenylindole. Cells were washed three times with PBS, coverslips were mounted in glycerol, and cells were visualized using an Olympus (Tokyo, Japan) confocal laser scanning microscope (FV10).
Statistical analysis
For cell-based experiments, the significance was evaluated using the Student ttest. All statistical analyses were performed using either GraphPad Prism for Mac 5.0 (GraphPad Software, Inc., La Jolla, CA) or Excel (Microsoft, Redmond, WA). P , 0.05 was considered statistically significant.
Results
In our previous study, we performed ChIP-seq analysis for AR and OCT1 to explore the distribution of OCT1binding regions throughout the human genome in two AR-dependent prostate cancer cell lines, LNCaP and VCaP (12) . We demonstrated that androgen treatment enhanced OCT1 recruitment around ARBSs, and these binding regions overlapped with ARBSs in the DHT-treated condition. To investigate the role of OCT1 in CRPC development, we performed a ChIP-seq study to determine global OCT1-binding genomic regions using AR-positive CRPC model 22Rv1 cells (25) . OCT1-binding regions were detected by calculating the enrichment of OCT1 compared with the input using the MACS software. In total, 30,497 binding regions were identified as OCT1-enriched sites in the absence of DHT, and 24,073 binding regions were identified in the presence of DHT (P , 1.0E-5) ( Fig. 1A) . Among the binding regions identified, 16,103 binding regions (52%) overlapped with ARBSs (P , 1.0E-5) in the absence of DHT, and 15,127 binding regions overlapped with ARBSs (62%) in the presence of DHT (Fig. 1B) . The OCT1 ChIP-seq revealed that the OCT family-binding motifs were highly enriched binding elements as examined by the HOMER program, suggesting that OCT1 binds to the genome sequences with OCT family-binding motifs directly (Fig. 1C) . The ChIP-seq data indicate that OCT1-binding regions were located in the promoter regions and distributed across the whole genome. In addition, OCT1 binding was increased by androgen treatment around the ARBSs (Fig. 1B) . We observed that the representative OCT1 target gene ACSL3 (12) exhibited signal enrichments in promoter and enhancer regions in 22Rv1 cells similar to that in LNCaP cells (Fig. 1D ).
Next, we compared the OCT1-binding regions and signals in 22Rv1 cells with those in LNCaP cells. Strikingly, around the signal peaks of significant ARBSs (P , 1.0E-5), ChIP-seq signals of AR and OCT1 increased in 22Rv1 cells, particularly in the absence of androgen compared with LNCaP cells ( Fig. 2A) . Therefore, clear overlapping between 22Rv1 and LNCaP OCT1-binding regions was observed in the presence of DHT. 22Rv1 cells had more OCT1-binding regions and different binding regions in the absence of DHT compared with LNCaP cells (Fig. 2B) . Western blot analysis showed that OCT1 protein level was elevated in 22Rv1 cells compared with LNCaP cells (Fig. 2C) . Thus, these results suggest that increased protein expression enhances OCT1 bindings in 22Rv1 cells in comparison with LNCaP cells.
Next, we focused on the role of OCT1 in androgenmediated transcription by using microarrays. In the previous study, we found that AR recruitment to specific promoters and androgen-dependent gene induction were severely blocked by OCT1 knockdown (12) . Thus, OCT1 has a positive role of modulating AR binding in AR-dependent transcription. To investigate the OCT1 target genes in CRPC model 22Rv1 cells, we treated the cells with siRNA targeting OCT1 (12) for 48 hours, followed by treatment with androgen or vehicle for 24 hours. Microarray analysis of gene expression and changes due to OCT1 depletion was performed. In total, the expression of 686 genes that had OCT1-binding regions within 3 kb from transcription start sites was decreased (fold , 0.5) in the absence of DHT by OCT1 knockdown and 486 genes in the presence of DHT (Fig. 3A) . We determined these genes to be OCT1regulated genes in 22Rv1 cells for further analysis. To examine the relationship between OCT1 binding and gene function, we performed functional analysis using Database for Annotation, Visualization and Integrated Discovery. We found that OCT1-regulated genes were associated with various functional annotation groups, which were strongly enriched for cell growth (cell cycle, DNA replication) and tumor progression (mismatch repair, spliceosome) ( Fig. 3B) . To explore the molecular mechanism for CRPC progression by OCT1, we further studied major downstream target genes regulated by OCT1 and the AR complex. We found that several genes, including ACSL3, were the most highly expressed genes regulated by AR and OCT1 in 22Rv1 cells (Fig. 3C ). Among these, we focused on the most highly induced gene, ANLN, in 22Rv1 specifically compared with LNCaP cells, indicating that ANLN could be the CRPCspecific OCT1 downstream target gene.
Although the functional role of ANLN in prostate cancer progression is still unclear, it has been identified as related to a more aggressive phenotype of clinical CRPCs in large scale using microarray analysis (30) . Knockdown of ANLN by siRNAs showed drastic repression of CRPC cell viability (30) . To analyze the correlation between OCT1 and ANLN in prostate cancer samples, we used another data set (31) of microarray-analyzing gene expressions in metastatic CRPC samples. Interestingly, OCT1 expression was enhanced in metastatic CRPC samples compared with benign and localized prostate cancer (Fig. 4A ). Accordingly, ANLN expression was also increased in the metastatic prostate cancer samples (Fig. 4B ). A positive correlation was observed between OCT1 and ANLN expression levels (Fig. 4C) , showing the important role of OCT1 in the regulation of ANLN in CRPC tissues.
We further analyzed the regulatory mechanism of ANLN by OCT1 and AR in 22Rv1 cells. Our ChIP-seq data (Fig. 5A ) revealed two major OCT1-binding regions in the promoter and intron regions. These OCT1-binding regions overlapped with ARBSs, and the signals were enhanced by androgen treatment. By using two sets of siRNAs targeting AR, we validated the regulation of ANLN expression by AR by qRT-PCR and Western blot analysis ( Fig. 5B and 5C ). Notably, siAR #2 significantly inhibited ANLN expression both in the absence and presence of DHT in 22Rv1 cells, although siAR #1 did only in the presence of DHT. Although siAR #1 targets the C-terminal region of AR, siAR #2 targets the N-terminal region of AR. Thus, knockdown of both AR and its splicing variants was achieved only in siAR #2 treatment (Fig. 5C ), suggesting the importance of AR variants for ANLN expression in the absence of DHT. Moreover, consistent with OCT1 knockdown efficiencies by three siRNAs targeting OCT1, significant repression of ANLN expression was observed at both the RNA (Fig. 5D ) and protein (Fig. 5E ) levels, demonstrating the regulatory role of OCT1 in ANLN expression.
In addition, we performed ChIP analysis to investigate the OCT1 bindings around CRPC-related OCT1 target genes. By performing ChIP assay for OCT1 and AR in 22Rv1 cells, we validated the distribution of OCT1 and AR in the enhancer region of ACSL3. We also observed increased enrichments in 22Rv1 cells compared with LNCaP cells, suggesting enhanced regulation of ACSL3 by OCT1 and AR (Fig. 6A) . Moreover, OCT1 recruitment to ANLN intron regions was also enhanced in 22Rv1 cells compared with LNCaP cells (Fig. 6B) . Although the enrichment of AR binding in ANLN was weak compared with that in the ACSL3 locus, AR binding in the promoter and intron regions was enhanced in 22Rv1 cells (Fig. 6B) . Taken together, these data suggest that enhanced expression of OCT1 and AR in CRPC promotes the expression of its target genes, such as ACSL3 and ANLN, for prostate cancer progression.
Next, we further investigated the role of ANLN in cell proliferation using siRNA targeting ANLN (Fig. 7A) . By immunofluorescence analysis, we observed expression of ANLN in the cell surface interacting with the actin filament during mitosis (M) (Fig. 7B ). ANLN knockdown showed disorganized cell shape during M compared with control cells, showing the important role of ANLN in cell shape in M. As shown in a previous report (30) , ANLN knockdown severely inhibited prostate cancer cell growth (Fig. 4C ). We further examined the role of ANLN in cell cycle progression in the M phase. After 18-hour treatment with nocodazole to synchronize cells at the G2/M phase, we refreshed the medium to promote the cell cycle. Western blot analysis of cyclin expressions revealed cell cycle progression of control cells by inducing cyclin D1 expression after repression of cyclin A (Fig. 7D ). However, after knocking down ANLN, we did not observe cyclin D1 induction, indicating the role of ANLN in cell cycle progression in the M phase. Interestingly, in the interphase, immunofluorescence analysis demonstrated that abnormally nucleated cells among siANLN-treated cells, which included discordant nuclei, were increased compared with control cells presumably because of cell division defects (Fig. 7E) . Moreover, ANLN expression was dominantly observed in the nucleus of control cells, suggesting that ANLN regulates cell cycles by transcriptional regulation.
Discussion
Our previous studies demonstrated that polyamides targeting the OCT1-binding sequence inhibit OCT1 genomic action and global androgen signaling, including ACSL3, which is the major transcriptional target of the AR/OCT1 complex. These data suggest that OCT1 could be the therapeutic target in advanced prostate cancer (12) . Genome-wide approaches that determine transcription factor-binding regions by ChIP-seq have been used to analyze the underlying mechanisms in prostate cancer progression (6, 7, 9, 10) . In the current study, we focused on the role of OCT1 in CRPC development by exploring the OCT1 occupancy in CRPC model 22Rv1 cells, which express high levels of AR and truncated variants of AR, such as AR-V7 (25) . In 22Rv1 cells, OCT1 bound to the specific binding regions that possess OCT family-binding motifs and overlapped with those in LNCaP cells. These findings suggest that the basal mechanism for OCT1 binding is not changed in CRPC compared with hormone-dependent cancer. However, we found that more OCT1-binding regions were obtained in 22Rv1 cells, possibly because OCT1 is highly expressed in 22Rv1 cells compared with LNCaP cells. In addition, we demonstrated that OCT1binding regions overlapped with ARBSs and that enrichment increased in 22Rv1 cells compared with ARdependent and hormone therapysensitive LNCaP prostate cancer cells. Moreover, our analysis using a public database indicates that OCT1 expression in metastatic prostate cancer tissues is increased compared with that in We demonstrated that one of the OCT1 target genes highly expressed in CRPC is ANLN. Overexpressed ANLN was reported in several cancers, and elevated expression appears to be involved in the metastatic potential of human cancers (32) (33) (34) (35) . A previous study reported that ANLN was overexpressed in hormone-refractory prostate cancer tissues (30) . Of note, the present report demonstrated that ANLN is the major target gene of the OCT1/AR complex in CRPC model cells. ANLN possesses a unique structure with multiple domains: actinbinding and myosin-binding domains at the N-terminus and a pleckstrin homology domain at the C-terminus (36) . ANLN is implicated in cytoskeletal dynamics for cytokinesis. In the telophase, it relocates to the cytoplasm, where it accumulates in the contractile ring and cleavage furrow (37) . Thus, ANLN promotes G2/M transition for cell proliferation (38) . In line with these reports, we also observed an important function of ANLN in cytoskeletal modulation during the M phase by immunofluorescence analysis, thus facilitating cell cycle progression. These findings indicate that ANLN has a role in cell cycle progression of CRPC cells to promote cell growth. In addition, ANLN interacts with activated RhoA, and this complex is likely important for the growth-promoting pathway and aggressive features of lung cancers through phosphatidylinositol-3-kinase/Akt signaling (32) . Another possible function of ANLN may be transcriptional regulation because it is located primarily in the nucleus of prostate cancer cells in the interphase. Thus, these findings suggest that ANLN regulates several oncogenic pathways to enhance cancer cell aggressiveness.
To determine whether the OCT1mediated transcriptional network could provide insight into functional relevance, we performed functional annotation clustering of OCT1-regulated genes. Notably, OCT1-binding genes were most associated with the cell cycle, which is a fundamental process for tumor and cancer cell growth. Surprisingly, we found 40 OCT1-regulated genes, such as ANLN, ZW10 interactor (ZWINT), and ubiquitinconjugating enzyme E2C (UBE2C), involved in G2/M cell cycle progression in this microarray analysis. Interestingly, CRPC-specific AR target genes were enriched in G2/Mrelated genes by the past comprehensive analysis of AR 22Rv1 cells were transfected with siControl or siANLN #1 or #2 (5 nM) for 72 h. Cells were then treated with nocodazole (1 mg/mL) for 18 h to synchronize cells at G2/M. Plates were washed with PBS, and cells were cultured in fresh medium for 0, 6, and 24 h. Cell cycle was analyzed by examining cyclin D1 and cyclin A expression levels by Western blot analysis. (E) Knockdown of ANLN showed discordant nuclei in 22Rv1 cells in the interphase. 22Rv1 cells were transfected with siControl or siANLN #1 (5 nM) for 72 h. Immunofluorescence analysis was performed to show the distribution of ANLN and actin in 22Rv1 cells in the interphase. Scale bar, 10 mm. Ct., siControl; DAPI, 4 0 ,6-diamidino-2-phenylindole; IB, immunoblot.
signaling in another CRPC model derived from LNCaP cells (5) . These results suggest that OCT1 could promote cell growth by promoting the cell cycle through regulation of G2/M-related genes in cooperation with AR. Another interesting OCT1 downstream characteristic in 22Rv1 cells was the spliceosome. We previously reported that spliceosome genes are universally upregulated in metastatic prostate cancer to dysregulate splicing activity in CRPC cells, indicating the importance of splicing factors in gene diversity during CRPC development (25) . Therefore, our finding showed that OCT1 upregulation in metastatic CRPC tissues could be involved in this spliceosome regulation.
We analyzed recruitments of OCT1 and AR to specific OCT1-binding regions identified in this study. We revealed ANLN as the most highly expressed gene specifically in 22Rv1 cells compared with LNCaP cells. This upregulation of ANLN in 22Rv1 cells could be illustrated by the upregulation of OCT1 recruitment to its enhancer regions in introns. Using the ChIP assay, we observed that AR bindings at both promoter and enhancer regions were enhanced in 22Rv1 cells. This result suggests that enhanced OCT1/AR binding at these regions increased the expression of ANLN in 22Rv1 cells.
In contrast to ANLN, ACSL3 was identified as a highly expressed gene in LNCaP cells (12) . In the current study, microarray analysis showed higher expression of ACSL3 in 22Rv1 cells than in LNCaP cells. ChIP analysis revealed enhancement of bindings of both AR and OCT1 at the ACSL3 enhancer region. Notably, the enrichment of bindings of both factors at the ACSL3 locus was higher than at the ANLN loci, suggesting that stronger AR/OCT1 binding at the ACSL3 enhancer induces the gene expression of ACSL3 in both LNCaP and 22Rv1 cells.
In conclusion, our study demonstrated that OCT1 binding was enhanced and was important for global AR-dependent gene activation in CRPC model cells. We found that AR/OCT1 downstream signaling, such as ANLN and ACSL3 activation, could promote prostate cancer progression. We therefore propose a model in which OCT1 functions as a key transcriptional mediator for prostate cancer progression to lethal CRPC, where AR signaling is highly activated.
